25-11-2021Print
Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials.
Positive Phase III results from two trials are to be presented on fitusiran at the upcoming American Society of Hematology (ASH) meeting.
Development of the drug has been far from plain sailing.
In 2017, clinical studies with fitusiran were placed on hold following reports of a fatal thrombotic event in…
This article is accessible to registered users, to continue reading pleaseregister for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.
Free
7 day trial access
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
£820
or £77 per month
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
Chairman, Sanofi Aventis UK
Alnylam PharmaceuticalsASHBiotechnologyConferencesDrug TrialfitusiranFranceHematologyResearchSanofiUSA
